Literature DB >> 25361479

The natural clinical course of hemodynamically stable adult moyamoya disease.

Won-Sang Cho1, Young Seob Chung, Jeong Eun Kim, Jin Pyeong Jeon, Young Je Son, Jae Seung Bang, Hyun-Seung Kang, Chul-Ho Sohn, Chang Wan Oh.   

Abstract

OBJECT: Moyamoya disease (MMD) is a rare cerebrovascular disease and its natural history is still unclear. The authors aimed to investigate the natural course of hemodynamically stable cases of adult MMD, with the analysis of stroke risk factors.
METHODS: Two hundred forty-one patients were included in this retrospective study. One hundred sixty-six (68.9%) were female, and mean age (± SD) at first visit was 41.3 ± 12.0 years (range 18-69 years). Unilateral involvement was identified in 33 patients, and 19 patients (7.9%) had a family history of MMD. According to the clinical presentations, patients were classified into hemorrhagic (n = 62, 25.7%), ischemic (n = 144, 59.8%), and asymptomatic (n = 35, 14.5%) groups. The mean duration of follow-up was 82.5 ± 62.9 months (range 7.3-347.0 months).
RESULTS: The annual stroke risk was 4.5%, and the annual risks of rebleeding in the hemorrhagic group and recurrent ischemic events in the ischemic group were 4.3% and 3.0%, respectively. There was no significant difference in cumulative stroke risk between the 3 groups (p = 0.461). Risk factors included thyroid disease for overall strokes (HR 2.56, 95% CI 1.16-5.67), initial hemorrhagic presentation for hemorrhagic strokes (HR 2.53, 95% CI 1.24-5.17), and initial ischemic presentation for ischemic strokes (HR 2.69, 95% CI 1.15-6.27). Familial MMD was a common risk factor for all types of stroke. Among the 3 clinical groups, the hemorrhagic group showed the worst clinical status at discharge and at most recent follow-up. Twenty-three patients (9.5%) eventually underwent revascularization surgery.
CONCLUSIONS: There was no statistically significant difference in the incidence of stroke in the different clinical groups; clinical status, however, was most severe in patients with hemorrhagic presentation. In patients who experienced stroke during the follow-up period, the stroke type tended to correspond to their initial presentation. Close follow-up is needed in patients with thyroid disease and a family history of MMD.

Entities:  

Keywords:  KPS = Karnofsky Performance Scale; MMD = moyamoya disease; SAH = subarachnoid hemorrhage; SPECT = single photon emission computed tomography; TIA = transient ischemic attack; asymptomatic; clinical course; hemorrhage; ischemia; mRS = modified Rankin Scale; moyamoya disease; vascular disorders

Mesh:

Year:  2015        PMID: 25361479     DOI: 10.3171/2014.9.JNS132281

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Moyamoya disease and moyamoya syndrome in Ireland: patient demographics, mode of presentation and outcomes of EC-IC bypass surgery.

Authors:  Ronan J Doherty; John Caird; Darach Crimmins; Peter Kelly; Sean Murphy; Christopher McGuigan; Niall Tubridy; Mary D King; Bryan Lynch; David Webb; Desmond O'Neill; Dominick J H McCabe; Peter Boers; Mary O'Regan; Joan Moroney; David J Williams; Simon Cronin; Mohsen Javadpour
Journal:  Ir J Med Sci       Date:  2020-06-19       Impact factor: 1.568

Review 2.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 3.  Moyamoya Disease: Treatment and Outcomes.

Authors:  Tackeun Kim; Chang Wan Oh; Jae Seung Bang; Jeong Eun Kim; Won-Sang Cho
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

4.  Moyamoya Disease with Coexistent Hypertriglyceridemia in Pediatric Patient.

Authors:  Jacqueline Chan; Fabiola D'Ambrosio Rodriguez; Deepank Sahni; Claudia Boucher-Berry
Journal:  Case Rep Endocrinol       Date:  2016-10-24

Review 5.  A Recent Update of Clinical and Research Topics Concerning Adult Moyamoya Disease.

Authors:  Jin Pyeong Jeon; Jeong Eun Kim
Journal:  J Korean Neurosurg Soc       Date:  2016-10-24

Review 6.  Late Cerebrovascular Events and Social Outcome after Adolescence: Long-term Outcome of Pediatric Moyamoya Disease.

Authors:  Takeshi Funaki; Jun C Takahashi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-21       Impact factor: 1.742

7.  The Efficacy of Surgical Treatment for the Secondary Prevention of Stroke in Symptomatic Moyamoya Disease: A Meta-Analysis.

Authors:  Cong Qian; Xiaobo Yu; Jianru Li; Jingyin Chen; Lin Wang; Gao Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

8.  Digital subtraction angiographic characteristics of progression of moyamoya disease 6 months prior to surgical revascularisation.

Authors:  Peicong Ge; Qian Zhang; Xun Ye; Xingju Liu; Xiaofeng Deng; Jia Wang; Rong Wang; Yan Zhang; Dong Zhang; Ji Zong Zhao
Journal:  Stroke Vasc Neurol       Date:  2020-02-27

9.  Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease.

Authors:  Chang Hwan Pang; Won-Sang Cho; Hyun-Seung Kang; Jeong Eun Kim
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

10.  A meta-analysis of comparisons of various surgical treatments for moyamoya diseases.

Authors:  Kai Lin; Shaohua Sui; Jing Zhao; Liyong Zhang; Kun Chen
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.